These findings highlight that HA-DOX-CDDP micelles integrate acid-sensitive drug release, CD44-targeted delivery, and excellent biocompatibility and biodegradability, making them a promising platform for enhanced chemotherapy in breast cancer [109]. Here, CD44 is linked to breast carcinoma.